Insider Trading Alert - OPK, CLX And CYN Traded By Insiders

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

Yesterday, March 19, 2014, 107 U.S. common stocks issued filings of shares being bought or sold by insiders. The transactions ranged in value from $699.00 to $189,034,125.00.

Highlighted Stocks Traded by Insiders:

Opko Health (OPK) - FREE Research Report

Frost Phillip Md Et Al who is CEO & Chairman at Opko Health bought 20,500 shares at $9.95 on March 19, 2014. Following this transaction, the CEO & Chairman owned 139.6 million shares meaning that the stake was reduced by 0.01% with the 20,500-share transaction.

The shares most recently traded at $9.74, down $0.21, or 2.16% since the insider transaction. Historical insider transactions for Opko Health go as follows:

  • 4-Week # shares bought: 10,000
  • 4-Week # shares sold: 46,730
  • 12-Week # shares bought: 30,000
  • 12-Week # shares sold: 46,730
  • 24-Week # shares bought: 30,000
  • 24-Week # shares sold: 46,730

The average volume for Opko Health has been 3.2 million shares per day over the past 30 days. Opko Health has a market cap of $4.1 billion and is part of the health care sector and health services industry. Shares are up 15.17% year-to-date as of the close of trading on Wednesday.

Opko Health, Inc., a biopharmaceutical and diagnostics company, is engaged in the discovery, development, and commercialization of novel and proprietary technologies. It operates in two segments, Pharmaceuticals and Diagnostics. Currently there are 3 analysts that rate Opko Health a buy, no analysts rate it a sell, and none rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on OPK - FREE

TheStreet Quant Ratings rates Opko Health as a hold. The company's strengths can be seen in multiple areas, such as its robust revenue growth, largely solid financial position with reasonable debt levels by most measures and expanding profit margins. However, as a counter to these strengths, we also find weaknesses including feeble growth in the company's earnings per share, deteriorating net income and weak operating cash flow. Get the full Opko Health Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

Clorox Company (CLX) - FREE Research Report

Tataseo Frank A who is EVP - Prof. Products Div. at Clorox Company sold 970 shares at $88.00 on March 19, 2014. Following this transaction, the EVP - Prof. Products Div. owned 3,754 shares meaning that the stake was reduced by 20.53% with the 970-share transaction.

The shares most recently traded at $87.27, down $0.73, or 0.84% since the insider transaction. Historical insider transactions for Clorox Company go as follows:

  • 4-Week # shares sold: 343
  • 12-Week # shares sold: 343
  • 24-Week # shares sold: 8,373

The average volume for Clorox Company has been 1.2 million shares per day over the past 30 days. Clorox Company has a market cap of $11.5 billion and is part of the consumer goods sector and consumer durables industry. Shares are down 4.88% year-to-date as of the close of trading on Wednesday.

The Clorox Company manufactures and markets consumer and professional products worldwide. The stock currently has a dividend yield of 3.22%. The company has a P/E ratio of 20.6. Currently there is 1 analyst that rates Clorox Company a buy, 5 analysts rate it a sell, and 7 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on CLX - FREE

TheStreet Quant Ratings rates Clorox Company as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, expanding profit margins, increase in stock price during the past year and notable return on equity. We feel these strengths outweigh the fact that the company has had generally high debt management risk by most measures that we evaluated. Get the full Clorox Company Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

City National (CYN) - FREE Research Report

Goldsmith Russell D who is Chairman, President and CEO at City National sold 11,014 shares at $75.46 on March 19, 2014. Following this transaction, the Chairman, President and CEO owned 253,916 shares meaning that the stake was reduced by 4.16% with the 11,014-share transaction.

The shares most recently traded at $79.15, up $3.69, or 4.66% since the insider transaction. Historical insider transactions for City National go as follows:

  • 4-Week # shares sold: 6,876
  • 12-Week # shares sold: 6,876
  • 24-Week # shares sold: 6,876

The average volume for City National has been 272,800 shares per day over the past 30 days. City National has a market cap of $4.2 billion and is part of the financial sector and banking industry. Shares are down 3.13% year-to-date as of the close of trading on Wednesday.

City National Corporation operates as the bank holding company for City National Bank that provides various banking, trust, and investment services to small to mid-sized businesses, entrepreneurs, professionals, and individuals. The stock currently has a dividend yield of 1.74%. The company has a P/E ratio of 19.0. Currently there are 3 analysts that rate City National a buy, 1 analyst rates it a sell, and 14 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on CYN - FREE

TheStreet Quant Ratings rates City National as a buy. The company's strengths can be seen in multiple areas, such as its growth in earnings per share, increase in net income, expanding profit margins, good cash flow from operations and solid stock price performance. We feel these strengths outweigh the fact that the company has had somewhat disappointing return on equity. Get the full City National Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

null

More from Markets

REPLAY: Jim Cramer on How to Navigate the Stock Market Amid Tariff Worries

REPLAY: Jim Cramer on How to Navigate the Stock Market Amid Tariff Worries

Global Markets Hit Hard; AMC Entertainment Sells Stake in Ad Unit -- ICYMI

Global Markets Hit Hard; AMC Entertainment Sells Stake in Ad Unit -- ICYMI

CVS, Walgreens and Citigroup: Cramer's 'Off the Charts'

CVS, Walgreens and Citigroup: Cramer's 'Off the Charts'

Jim Cramer: 4 Stocks Could Get Throttled By a 'Knock Down Drag Out' With China

Jim Cramer: 4 Stocks Could Get Throttled By a 'Knock Down Drag Out' With China

General Electric Booted From Dow, Replaced by Walgreens

General Electric Booted From Dow, Replaced by Walgreens